Pre-hospital ARNI use and short-term outcomes in HFrEF
Evaluating the Impact of Pre-Hospital Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy on Short-Term Clinical Outcomes in Heart Failure Patients With Reduced Ejection Fraction: A Comparative Study
This project will see if people with heart failure and low ejection fraction who were taking an ARNI before coming to the hospital have better short-term outcomes than those who weren't.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Future University in Egypt Academic / other |
| Locations | 1 site (Al Mansurah) |
| Trial ID | NCT07347925 on ClinicalTrials.gov |
What this trial studies
This observational study compares adults admitted with heart failure and left ventricular ejection fraction under 40% who were taking an angiotensin receptor–neprilysin inhibitor (sacubitril/valsartan) before hospital arrival to those who were not. Investigators will extract data from hospital records to record cardiac events, kidney-related events, length of stay, and selected short-term outcomes, with some participants followed briefly after discharge. No treatments are assigned as part of the study; analyses will adjust for baseline clinical differences to explore associations between pre-hospital ARNI use and outcomes. The work is conducted at a single center (Mansoura University Hospital) and reflects routine clinical care in that setting.
Who should consider this trial
Good fit: Adults aged 18 or older hospitalized with heart failure and an ejection fraction below 40% with verifiable pre-admission medication history are the ideal candidates.
Not a fit: Patients with preserved ejection fraction (>40%), pregnant or breastfeeding individuals, or those without reliable medication records are unlikely to be included or to directly benefit from the study findings.
Why it matters
Potential benefit: If positive, the results could clarify whether prior ARNI use is linked to fewer in-hospital cardiac or renal complications and shorter hospital stays, informing real-world management of HFrEF.
How similar studies have performed: Randomized trials have shown long-term mortality and morbidity benefits of sacubitril/valsartan in HFrEF, but evidence specifically about pre-hospital ARNI use and short-term in-hospital outcomes is limited and mainly observational.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>= 18 years, male or female EF \<40% Exclusion Criteria: * EF\>40% Pregnancy or breastfeeding
Where this trial is running
Al Mansurah
- Mansoura university Hospital — Al Mansurah, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.